Nasopharyngeal carcinoma
Information
- Disease name
- Nasopharyngeal carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT03240835 | Active, not recruiting | The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients | September 12, 2017 | December 31, 2023 | |
| NCT06442709 | Active, not recruiting | N/A | Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients | August 1, 2021 | July 1, 2024 |
| NCT03267498 | Active, not recruiting | Phase 2 | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | February 14, 2018 | April 30, 2024 |
| NCT03840421 | Active, not recruiting | Phase 3 | GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | April 3, 2019 | December 31, 2028 |
| NCT04223024 | Active, not recruiting | Phase 2 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | December 12, 2019 | December 2026 |
| NCT04242199 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | September 4, 2020 | October 31, 2025 |
| NCT03855020 | Active, not recruiting | Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients | May 9, 2019 | May 1, 2024 | |
| NCT03047265 | Active, not recruiting | Phase 2 | Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | February 4, 2017 | June 1, 2027 |
| NCT04272034 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | March 26, 2021 | June 20, 2026 |
| NCT05576272 | Active, not recruiting | Phase 2/Phase 3 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | May 19, 2022 | December 30, 2024 |
| NCT03321539 | Active, not recruiting | Phase 3 | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | October 30, 2017 | December 31, 2025 |
| NCT05520814 | Active, not recruiting | Phase 2 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | August 1, 2018 | December 31, 2023 |
| NCT03708822 | Active, not recruiting | Phase 2 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | October 15, 2018 | June 30, 2024 |
| NCT04384627 | Active, not recruiting | Phase 3 | Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy | December 1, 2019 | October 1, 2026 |
| NCT02597426 | Active, not recruiting | Nasopharyngeal Carcinoma Post IMRT | June 2015 | December 2024 | |
| NCT03752398 | Active, not recruiting | Phase 1 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | May 1, 2019 | September 2025 |
| NCT04398056 | Active, not recruiting | Phase 2 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | April 1, 2019 | July 1, 2024 |
| NCT03866967 | Active, not recruiting | Phase 2 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma | March 27, 2019 | April 13, 2024 |
| NCT04405622 | Active, not recruiting | Phase 2 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | May 30, 2020 | May 2023 |
| NCT02501993 | Active, not recruiting | Nasopharyngeal Carcinoma Screening in Zhongshan City | March 2012 | December 2023 | |
| NCT05294172 | Active, not recruiting | Phase 3 | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | June 16, 2022 | May 31, 2025 |
| NCT03891953 | Active, not recruiting | Phase 1 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | May 7, 2019 | September 12, 2024 |
| NCT05211232 | Active, not recruiting | Phase 3 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | June 10, 2022 | May 30, 2028 |
| NCT02460887 | Active, not recruiting | Phase 3 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | June 2015 | April 2024 |
| NCT03306121 | Active, not recruiting | Phase 3 | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma | November 13, 2017 | December 31, 2026 |
| NCT04586088 | Active, not recruiting | Phase 2 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | May 5, 2020 | September 5, 2023 |
| NCT04907370 | Active, not recruiting | Phase 3 | PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma | August 1, 2021 | May 1, 2027 |
| NCT03925090 | Active, not recruiting | Phase 2 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | December 8, 2019 | October 2023 |
| NCT04996758 | Active, not recruiting | Phase 2 | Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) | October 30, 2021 | October 2026 |
| NCT02063399 | Active, not recruiting | Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | July 2013 | June 2023 | |
| NCT03984357 | Active, not recruiting | Phase 2 | Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | March 16, 2020 | March 30, 2026 |
| NCT04072107 | Active, not recruiting | Phase 2 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) | June 1, 2020 | December 1, 2024 |
| NCT04929080 | Completed | Phase 1/Phase 2 | The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC | May 11, 2021 | March 6, 2023 |
| NCT04094545 | Completed | Intestinal Flora Sequencing for Nasopharyngeal Carcinoma | August 1, 2018 | May 30, 2019 | |
| NCT03558191 | Completed | Phase 2 | SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. | August 14, 2018 | December 30, 2021 |
| NCT03427359 | Completed | Phase 2 | Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | January 22, 2015 | December 31, 2017 |
| NCT03429868 | Completed | N/A | PET and MRI in Prognosis Prediction of NPC | August 1, 2015 | July 31, 2020 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT00341146 | Completed | Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) | April 1, 2001 | September 20, 2006 | |
| NCT00379262 | Completed | Phase 3 | Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma | September 2006 | December 2018 |
| NCT00431210 | Completed | Phase 1 | Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | February 2007 | January 26, 2016 |
| NCT00516087 | Completed | Phase 1 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | August 2007 | July 2013 |
| NCT00535795 | Completed | Phase 3 | Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA | September 2007 | September 2015 |
| NCT00592501 | Completed | Phase 2 | Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma | October 2006 | April 2019 |
| NCT00697905 | Completed | Phase 2 | Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma | January 2008 | May 2011 |
| NCT00700440 | Completed | Phase 2 | Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy | July 2008 | April 2009 |
| NCT06367049 | Completed | Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma | June 1, 2023 | March 1, 2024 | |
| NCT00778908 | Completed | Phase 2/Phase 3 | Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma | January 2008 | December 2011 |
| NCT06244394 | Completed | Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma | June 1, 2023 | December 10, 2023 | |
| NCT00834093 | Completed | Phase 2 | A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | April 2009 | February 2017 |
| NCT00953420 | Completed | Phase 2 | Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes | November 2009 | July 2015 |
| NCT01187238 | Completed | Phase 2 | The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma | May 2010 | October 2017 |
| NCT01271439 | Completed | Phase 2 | Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma | September 2010 | December 2012 |
| NCT01309633 | Completed | Phase 2 | Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) | September 2, 2011 | March 11, 2019 |
| NCT01326559 | Completed | Phase 2 | Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) | June 2010 | March 2017 |
| NCT01344356 | Completed | Phase 4 | Stereotactic Body Radiotherapy for Head and Neck Tumors | July 2008 | May 2018 |
| NCT01447056 | Completed | Phase 1 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | February 2012 | January 22, 2020 |
| NCT01449942 | Completed | Phase 1/Phase 2 | Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma | May 2009 | September 2011 |
| NCT01534585 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma | February 2012 | February 2015 |
| NCT01540136 | Completed | Phase 3 | Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma | February 2012 | July 2016 |
| NCT01621880 | Completed | Phase 2 | Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma | June 2012 | December 2015 |
| NCT01712919 | Completed | Phase 1/Phase 2 | Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) | May 2010 | March 2014 |
| NCT01865201 | Completed | Phase 2 | Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis | March 2009 | September 2012 |
| NCT02012062 | Completed | Phase 3 | Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC | July 2012 | August 2017 |
| NCT05020067 | Completed | Phase 2 | Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy | January 12, 2018 | August 17, 2021 |
| NCT04995185 | Completed | N/A | 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study | June 20, 2017 | December 30, 2020 |
| NCT02523430 | Completed | Phase 1/Phase 2 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma | May 2015 | June 2016 |
| NCT02562599 | Completed | Phase 2 | Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin | August 2015 | August 2018 |
| NCT02575547 | Completed | Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients | June 2015 | June 2020 | |
| NCT02578641 | Completed | Phase 3 | A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients | July 2014 | February 28, 2022 |
| NCT02584790 | Completed | N/A | NBI to Detect Post-RT Mucosal Residual NPC | November 2015 | April 2017 |
| NCT04396886 | Completed | Phase 2 | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC | February 27, 2020 | July 26, 2023 |
| NCT02605967 | Completed | Phase 2 | Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | April 20, 2016 | February 19, 2021 |
| NCT00188253 | Completed | Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma. | March 2005 | February 2017 | |
| NCT04394065 | Completed | uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma | June 20, 2020 | June 20, 2021 | |
| NCT04387266 | Completed | To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC | June 1, 2020 | October 1, 2020 | |
| NCT04350190 | Completed | Phase 2 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | January 14, 2021 | September 15, 2022 |
| NCT02642107 | Completed | Phase 3 | Individualized Elective Neck Irradiation Based on MRI in NPC Patients | January 2016 | May 2018 |
| NCT02776124 | Completed | Phase 2 | Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients | June 2014 | January 2018 |
| NCT04220307 | Completed | Phase 2 | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma | April 26, 2020 | August 23, 2022 |
| NCT04108338 | Completed | Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma | June 1, 2019 | August 1, 2019 | |
| NCT03398980 | Completed | Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy | September 2, 2016 | January 10, 2017 | |
| NCT03989297 | Completed | PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma | January 1, 2017 | December 30, 2019 | |
| NCT03981224 | Completed | The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients | May 2, 2012 | May 1, 2013 | |
| NCT02940925 | Completed | Phase 3 | TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma | October 20, 2016 | August 31, 2021 |
| NCT03973723 | Completed | Plasma EBV DNA Monitoring in Post-treatment NPC Patients | August 1, 2011 | April 30, 2019 | |
| NCT03906058 | Completed | Phase 2 | Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy | April 29, 2019 | April 30, 2022 |
| NCT03876574 | Completed | Phase 1 | Hepatic Artery Infusion Pump for NPC Liver Metastases | January 1, 2011 | December 31, 2017 |
| NCT03025958 | Completed | Phase 2 | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | March 13, 2017 | December 30, 2023 |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT03848286 | Completed | Phase 2 | KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma | March 6, 2019 | January 13, 2022 |
| NCT03810274 | Completed | 3DV+TPS Software Outlines the Radiotherapy of Nasopharyngeal Carcinoma | February 1, 2012 | January 15, 2019 | |
| NCT03121716 | Completed | Phase 1 | A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects | April 26, 2017 | July 31, 2020 |
| NCT03788499 | Completed | N/A | Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral Mucositis | January 11, 2019 | July 30, 2020 |
| NCT03283293 | Completed | Phase 2 | Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT | February 2001 | April 2008 |
| NCT03670342 | Completed | Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer | August 20, 2015 | April 15, 2019 | |
| NCT03314051 | Completed | Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA | May 2, 2012 | December 31, 2016 | |
| NCT03668366 | Completed | Phase 2 | S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | August 1, 2013 | August 1, 2020 |
| NCT03601390 | Completed | Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC | October 1, 2018 | December 12, 2020 | |
| NCT00201396 | Completed | Phase 3 | A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma | August 2003 | December 2011 |
| NCT00212108 | Completed | Phase 1/Phase 2 | A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 | November 2003 | January 2009 |
| NCT03379610 | Completed | A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy | January 2006 | December 2018 | |
| NCT03389295 | Completed | Phase 2 | Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | January 2010 | April 2019 |
| NCT03598218 | Completed | N/A | Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma | July 13, 2018 | April 10, 2022 |
| NCT02199132 | Completed | Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli | July 2014 | October 2014 | |
| NCT02237924 | Completed | Phase 2 | Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma | September 2014 | January 2022 |
| NCT00173836 | Completed | Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount | August 2003 | August 2006 | |
| NCT04834206 | Completed | Phase 2 | Nedaplatin in Treatment for Nasopharyngeal Carcinoma | May 1, 2021 | May 1, 2022 |
| NCT04736810 | Completed | Phase 2 | A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma | March 4, 2021 | December 18, 2023 |
| NCT04636632 | Completed | Phase 1 | Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | November 24, 2020 | November 4, 2022 |
| NCT02460419 | Completed | Phase 3 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | April 2015 | May 2020 |
| NCT04508816 | Completed | Phase 2 | Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | January 1, 2016 | October 1, 2020 |
| NCT04417985 | Completed | N/A | Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma | August 1, 2011 | July 31, 2014 |
| NCT04917770 | Not yet recruiting | Phase 2 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | June 30, 2021 | June 30, 2024 |
| NCT05092217 | Not yet recruiting | Phase 2 | Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | October 20, 2021 | October 20, 2024 |
| NCT06197776 | Not yet recruiting | Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC | April 1, 2024 | December 30, 2026 | |
| NCT05622474 | Not yet recruiting | N/A | A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy | November 30, 2022 | December 31, 2028 |
| NCT05780294 | Not yet recruiting | Phase 3 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | April 1, 2023 | December 1, 2029 |
| NCT04890522 | Not yet recruiting | Phase 2/Phase 3 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | July 1, 2021 | December 31, 2028 |
| NCT06323239 | Not yet recruiting | Phase 2 | SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma | April 1, 2024 | April 1, 2028 |
| NCT04769076 | Not yet recruiting | Phase 2 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | March 1, 2021 | December 1, 2025 |
| NCT04766359 | Not yet recruiting | Phase 3 | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma | March 1, 2021 | August 1, 2025 |
| NCT05898256 | Not yet recruiting | Phase 1/Phase 2 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | August 1, 2023 | July 31, 2026 |
| NCT06349889 | Not yet recruiting | Phase 2 | Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma | May 1, 2024 | May 1, 2028 |
| NCT04605562 | Not yet recruiting | Phase 2 | Umbrella Biomarker-Guided Therapy in NPC | June 2022 | December 2026 |
| NCT05183724 | Not yet recruiting | Ovarian Function of Nasopharyngeal Carcinoma Women Survivors | January 10, 2022 | January 10, 2026 | |
| NCT06389201 | Not yet recruiting | N/A | Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients | May 1, 2024 | December 31, 2026 |
| NCT05193617 | Not yet recruiting | Phase 2 | Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | January 20, 2022 | January 1, 2027 |
| NCT04534855 | Not yet recruiting | Phase 2 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | September 1, 2020 | September 1, 2025 |
| NCT06059261 | Not yet recruiting | Phase 2 | Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. | October 1, 2023 | October 1, 2027 |
| NCT04447326 | Not yet recruiting | Phase 2 | Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma | June 2020 | June 2026 |
| NCT05340270 | Not yet recruiting | Phase 2 | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma | August 1, 2022 | July 31, 2026 |
| NCT06438627 | Not yet recruiting | Phase 3 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | May 30, 2024 | May 30, 2029 |
| NCT06463392 | Not yet recruiting | Deep Learning-based sbORN Diagnostic Model | June 20, 2024 | December 31, 2030 | |
| NCT06093061 | Not yet recruiting | Phase 2 | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | December 2023 | October 2029 |
| NCT04414566 | Not yet recruiting | Phase 3 | Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | June 1, 2020 | May 30, 2025 |
| NCT06364826 | Not yet recruiting | Phase 2 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | April 22, 2024 | April 22, 2026 |
| NCT05341193 | Not yet recruiting | Phase 1/Phase 2 | PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | April 30, 2022 | December 30, 2025 |
| NCT06095167 | Not yet recruiting | Phase 3 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | January 1, 2024 | January 1, 2028 |
| NCT03503136 | Not yet recruiting | Phase 3 | Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC | June 2018 | June 2026 |
| NCT05417139 | Not yet recruiting | Phase 2 | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study | July 1, 2022 | July 1, 2025 |
| NCT06455410 | Not yet recruiting | Phase 2 | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma | June 17, 2024 | June 17, 2028 |
| NCT03529279 | Not yet recruiting | Phase 3 | CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy | June 12, 2018 | June 12, 2026 |
| NCT05433597 | Not yet recruiting | Phase 2/Phase 3 | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | July 1, 2022 | July 1, 2029 |
| NCT06129201 | Not yet recruiting | Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging | November 15, 2023 | December 1, 2025 | |
| NCT03290820 | Not yet recruiting | Phase 2 | Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients | January 1, 2018 | September 30, 2024 |
| NCT06136962 | Not yet recruiting | Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life | December 1, 2023 | December 1, 2024 | |
| NCT06370026 | Not yet recruiting | Early Phase 1 | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | May 1, 2024 | December 31, 2026 |
| NCT05519956 | Not yet recruiting | Phase 3 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | September 16, 2022 | September 30, 2025 |
| NCT04351282 | Not yet recruiting | N/A | SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma | June 1, 2020 | May 31, 2026 |
| NCT06383507 | Not yet recruiting | Phase 1 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | April 22, 2024 | April 21, 2029 |
| NCT05884983 | Recruiting | Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma | February 1, 2023 | December 31, 2024 | |
| NCT02287311 | Recruiting | Phase 1 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | February 2015 | March 2029 |
| NCT02512315 | Recruiting | Phase 3 | A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma | August 2015 | December 2024 |
| NCT02610010 | Recruiting | Phase 3 | Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma | November 2015 | November 2025 |
| NCT03097939 | Recruiting | Phase 2 | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | March 31, 2017 | December 31, 2024 |
| NCT03353467 | Recruiting | N/A | Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients | October 1, 2017 | October 1, 2028 |
| NCT03366415 | Recruiting | Phase 3 | Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC | January 1, 2018 | December 30, 2024 |
| NCT03657017 | Recruiting | N/A | PET/MR in Locally Advanced Nasopharyngeal Carcinoma | June 1, 2018 | December 30, 2025 |
| NCT03809624 | Recruiting | Phase 2 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | January 30, 2019 | December 2025 |
| NCT03837808 | Recruiting | Phase 3 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | April 11, 2019 | February 11, 2024 |
| NCT03942380 | Recruiting | N/A | Cell-free Tumor DNA in Head and Neck Cancer Patients | February 1, 2017 | February 1, 2025 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04085900 | Recruiting | Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City | April 1, 2020 | December 31, 2027 | |
| NCT04136886 | Recruiting | Phase 3 | Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma | January 1, 2020 | December 2027 |
| NCT04143984 | Recruiting | Phase 2 | Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma | January 19, 2021 | December 20, 2025 |
| NCT04221516 | Recruiting | Phase 2 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | January 1, 2020 | February 1, 2024 |
| NCT04227509 | Recruiting | Phase 2 | Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | June 4, 2020 | December 31, 2025 |
| NCT04436965 | Recruiting | Phase 3 | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition | August 16, 2021 | December 15, 2024 |
| NCT04437329 | Recruiting | Phase 3 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | August 1, 2020 | June 30, 2029 |
| NCT04447612 | Recruiting | Phase 2 | Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma | June 1, 2020 | December 31, 2024 |
| NCT04448522 | Recruiting | Phase 3 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma | August 18, 2020 | August 2028 |
| NCT04453813 | Recruiting | Phase 3 | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | July 3, 2020 | July 2027 |
| NCT04456322 | Recruiting | Phase 3 | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | July 6, 2020 | June 1, 2025 |
| NCT04509726 | Recruiting | Phase 1/Phase 2 | EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma | March 2023 | August 2023 |
| NCT04517214 | Recruiting | Phase 2 | Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma | November 1, 2020 | December 31, 2026 |
| NCT04522050 | Recruiting | Phase 1 | Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | October 1, 2018 | December 1, 2024 |
| NCT04544969 | Recruiting | Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC | April 1, 2020 | December 31, 2025 | |
| NCT04557020 | Recruiting | Phase 3 | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC | December 30, 2020 | March 1, 2026 |
| NCT04593186 | Recruiting | N/A | Magnifying NBI for Occult NPC | April 15, 2021 | November 30, 2024 |
| NCT04778956 | Recruiting | Phase 3 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | March 3, 2021 | March 3, 2033 |
| NCT04813705 | Recruiting | Phase 2 | 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma | January 1, 2022 | June 30, 2029 |
| NCT04823468 | Recruiting | N/A | Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma | July 19, 2021 | September 2025 |
| NCT04825990 | Recruiting | Phase 2 | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer | March 24, 2022 | March 24, 2028 |
| NCT04830267 | Recruiting | Phase 2 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | March 1, 2021 | August 1, 2026 |
| NCT04833257 | Recruiting | Phase 2 | Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC | April 14, 2021 | November 30, 2026 |
| NCT04898374 | Recruiting | Phase 3 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | May 1, 2021 | April 30, 2026 |
| NCT04944914 | Recruiting | Phase 3 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | June 1, 2021 | June 1, 2026 |
| NCT04974398 | Recruiting | Phase 3 | A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | August 16, 2021 | September 15, 2026 |
| NCT04978012 | Recruiting | Phase 2 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | July 25, 2021 | December 31, 2025 |
| NCT05037357 | Recruiting | Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements | August 1, 2021 | June 2024 | |
| NCT05097209 | Recruiting | Phase 2 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | April 6, 2022 | April 6, 2026 |
| NCT05099978 | Recruiting | Asian Multicenter Prospective Study of ctDNA Sequencing | November 1, 2021 | December 31, 2024 | |
| NCT05126160 | Recruiting | Immune Score Based Radiomics in Nasopharyngeal Carcinoma | November 5, 2021 | December 2027 | |
| NCT05145660 | Recruiting | Phase 3 | Optimization of Cervical Nodal CTV for Early and Medium Stage NPC | September 1, 2022 | August 31, 2027 |
| NCT05147844 | Recruiting | Phase 2 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | March 1, 2022 | March 1, 2026 |
| NCT05166577 | Recruiting | Phase 1/Phase 2 | Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC | October 8, 2021 | October 2025 |
| NCT05177237 | Recruiting | Phase 2 | Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma | July 28, 2021 | December 30, 2025 |
| NCT05201859 | Recruiting | Phase 2 | Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | March 29, 2022 | February 15, 2026 |
| NCT05202626 | Recruiting | Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images | December 1, 2021 | June 28, 2025 | |
| NCT05229315 | Recruiting | Phase 2 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | March 12, 2022 | December 2023 |
| NCT05232552 | Recruiting | Phase 2 | Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma | January 1, 2021 | December 31, 2024 |
| NCT05290194 | Recruiting | Phase 2 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | March 28, 2022 | January 1, 2027 |
| NCT05304468 | Recruiting | Phase 3 | Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain | March 29, 2022 | April 1, 2026 |
| NCT05340491 | Recruiting | Phase 3 | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | April 1, 2022 | December 2027 |
| NCT05342792 | Recruiting | Phase 3 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | April 17, 2022 | June 2029 |
| NCT05352321 | Recruiting | N/A | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma | June 1, 2022 | June 1, 2028 |
| NCT05389306 | Recruiting | N/A | Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients | May 25, 2022 | December 31, 2024 |
| NCT05415098 | Recruiting | Phase 1 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | September 30, 2022 | September 30, 2025 |
| NCT05431764 | Recruiting | Phase 2 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | June 20, 2022 | June 20, 2026 |
| NCT05447169 | Recruiting | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | July 10, 2022 | July 1, 2030 | |
| NCT05448885 | Recruiting | Phase 2 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | September 1, 2021 | December 31, 2025 |
| NCT05508347 | Recruiting | Phase 2 | Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma | August 15, 2022 | September 15, 2023 |
| NCT05514275 | Recruiting | Phase 2 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | August 1, 2022 | August 1, 2028 |
| NCT05517135 | Recruiting | Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study | November 17, 2022 | July 1, 2027 | |
| NCT05524168 | Recruiting | Phase 2 | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma | November 25, 2022 | September 2025 |
| NCT05527470 | Recruiting | Phase 3 | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | November 11, 2022 | November 11, 2027 |
| NCT05531916 | Recruiting | N/A | Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial | November 21, 2022 | December 31, 2024 |
| NCT05544929 | Recruiting | Phase 1 | A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | October 26, 2022 | February 20, 2026 |
| NCT05547971 | Recruiting | Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics | September 2022 | June 2023 | |
| NCT05549466 | Recruiting | Phase 2 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | October 8, 2022 | September 20, 2025 |
| NCT05563272 | Recruiting | Phase 2 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | June 6, 2023 | December 29, 2025 |
| NCT05563480 | Recruiting | Phase 2 | TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | October 27, 2022 | May 2024 |
| NCT05587374 | Recruiting | Phase 3 | Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | August 1, 2023 | January 1, 2027 |
| NCT05587543 | Recruiting | Early Phase 1 | Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma | December 28, 2022 | October 2030 |
| NCT05616468 | Recruiting | Early Phase 1 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | December 30, 2022 | December 31, 2025 |
| NCT05626829 | Recruiting | Phase 2 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | July 20, 2022 | November 30, 2024 |
| NCT05627310 | Recruiting | Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images | November 1, 2022 | March 31, 2024 | |
| NCT05654077 | Recruiting | Early Phase 1 | EBV CAR-T Cells for Nasopharyngeal Carcinoma | January 18, 2022 | December 30, 2025 |
| NCT05674305 | Recruiting | Phase 3 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | January 1, 2022 | January 1, 2027 |
| NCT05682703 | Recruiting | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma. | December 23, 2022 | December 20, 2025 | |
| NCT05707819 | Recruiting | Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | July 30, 2022 | December 31, 2028 | |
| NCT05721222 | Recruiting | Phase 1/Phase 2 | PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) | March 15, 2023 | April 30, 2025 |
| NCT05724355 | Recruiting | Phase 2 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | September 1, 2022 | October 2024 |
| NCT05741008 | Recruiting | N/A | Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma | January 31, 2023 | December 31, 2024 |
| NCT05771025 | Recruiting | N/A | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases | April 1, 2023 | December 2025 |
| NCT05772208 | Recruiting | Phase 3 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | January 1, 2022 | January 1, 2028 |
| NCT05780372 | Recruiting | Phase 3 | Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma | August 8, 2023 | August 2029 |
| NCT05790200 | Recruiting | Phase 2 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | April 1, 2023 | September 22, 2025 |
| NCT05813626 | Recruiting | Phase 2 | Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | April 3, 2023 | October 30, 2027 |
| NCT05834712 | Recruiting | N/A | Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention | May 11, 2022 | December 2023 |
| NCT05854849 | Recruiting | Phase 3 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | May 1, 2023 | December 1, 2027 |
| NCT05869227 | Recruiting | Phase 3 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | April 28, 2023 | April 28, 2029 |
| NCT05877872 | Recruiting | Phase 3 | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma | May 20, 2023 | March 30, 2029 |
| NCT05893810 | Recruiting | Phase 3 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | July 1, 2023 | December 31, 2024 |
| NCT05904080 | Recruiting | Phase 2 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | February 19, 2024 | June 16, 2028 |
| NCT05913414 | Recruiting | Phase 2 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | May 5, 2023 | May 30, 2026 |
| NCT05941741 | Recruiting | Phase 3 | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | January 10, 2024 | December 2029 |
| NCT05949749 | Recruiting | A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC | August 25, 2023 | September 30, 2024 | |
| NCT05955105 | Recruiting | Phase 1/Phase 2 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | July 25, 2023 | July 24, 2026 |
| NCT05956587 | Recruiting | Phase 2 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | January 29, 2024 | November 2025 |
| NCT05979961 | Recruiting | Phase 3 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | September 7, 2023 | September 2027 |
| NCT05981157 | Recruiting | Phase 2 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | June 1, 2023 | December 30, 2025 |
| NCT05994170 | Recruiting | N/A | Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma | August 4, 2023 | September 1, 2029 |
| NCT06019130 | Recruiting | Phase 2 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | January 10, 2023 | January 9, 2028 |
| NCT06026878 | Recruiting | Phase 3 | GNT Induction Treatment in Locally Advanced NPC | September 1, 2023 | September 30, 2027 |
| NCT06032767 | Recruiting | Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning | August 14, 2023 | December 30, 2024 | |
| NCT06055816 | Recruiting | Phase 2 | Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma | September 28, 2023 | June 30, 2028 |
| NCT06092957 | Recruiting | Phase 3 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | October 9, 2023 | October 30, 2031 |
| NCT06097793 | Recruiting | Early Phase 1 | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | December 4, 2023 | December 31, 2025 |
| NCT06118333 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | December 4, 2023 | December 2025 |
| NCT06156878 | Recruiting | Phase 2 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | August 1, 2022 | August 2025 |
| NCT06170021 | Recruiting | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy | December 6, 2023 | December 6, 2025 | |
| NCT06177301 | Recruiting | Phase 3 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | December 1, 2023 | December 2027 |
| NCT06182657 | Recruiting | The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | January 1, 2024 | June 30, 2029 | |
| NCT06239727 | Recruiting | Phase 3 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | March 1, 2024 | February 20, 2030 |
| NCT06241612 | Recruiting | Phase 3 | Individualized Elective Neck Irradiation in NPC Patients | April 16, 2024 | March 2031 |
| NCT06259721 | Recruiting | Phase 2 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | February 10, 2024 | August 9, 2026 |
| NCT06268600 | Recruiting | N/A | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma | January 1, 2019 | November 30, 2025 |
| NCT06277050 | Recruiting | Phase 3 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | March 7, 2024 | February 20, 2030 |
| NCT06301165 | Recruiting | Phase 2 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | March 19, 2024 | December 31, 2028 |
| NCT06307314 | Recruiting | Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis | February 1, 2024 | December 31, 2026 | |
| NCT06313450 | Recruiting | N/A | De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma | March 4, 2024 | February 1, 2028 |
| NCT06321939 | Recruiting | Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma | January 11, 2024 | December 31, 2028 | |
| NCT06383780 | Recruiting | Phase 3 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | May 15, 2024 | May 15, 2029 |
| NCT06445088 | Recruiting | Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma | May 29, 2024 | December 31, 2026 | |
| NCT02022293 | Suspended | Phase 2 | Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis | January 2017 | January 2024 |
| NCT02058017 | Terminated | Phase 1 | OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy | November 2013 | May 2015 |
| NCT01694576 | Terminated | Phase 2 | NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation | September 2012 | October 2015 |
| NCT02698111 | Terminated | Phase 1/Phase 2 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | February 8, 2017 | October 20, 2021 |
| NCT03769467 | Terminated | Phase 1/Phase 2 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | February 19, 2019 | August 19, 2021 |
| NCT06189482 | Terminated | N/A | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma | June 1, 2022 | December 31, 2022 |
| NCT02582008 | Terminated | Early Phase 1 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | January 2016 | September 6, 2019 |
| NCT02801487 | Terminated | Phase 1/Phase 2 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | September 2015 | January 2017 |
| NCT01230476 | Terminated | Phase 2 | Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma | May 2010 | May 2015 |
| NCT02569788 | Terminated | Phase 1/Phase 2 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | September 2015 | May 1, 2017 |
| NCT06248840 | Terminated | N/A | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma | June 1, 2022 | December 31, 2022 |
| NCT03682055 | Terminated | Phase 1/Phase 2 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | April 4, 2019 | August 8, 2020 |
| NCT03544099 | Terminated | Phase 2 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | May 7, 2019 | December 31, 2021 |
| NCT00201344 | Terminated | Phase 3 | A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients | November 1994 | January 2000 |
| NCT01403259 | Terminated | Phase 2 | SOX as Salvage Treatment in Nasopharyngeal Carcinoma | July 2011 | December 2015 |
| NCT05008471 | Unknown status | N/A | Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study | April 26, 2021 | April 26, 2022 |
| NCT02044562 | Unknown status | N/A | Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients | September 2013 | September 2014 |
| NCT05020925 | Unknown status | Phase 1/Phase 2 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | September 2021 | February 2024 |
| NCT00634595 | Unknown status | Phase 2 | Trial of E10A in Head and Neck Cancer | March 2008 | December 2010 |
| NCT01265147 | Unknown status | Phase 2 | Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma | January 2011 | December 2017 |
| NCT01245959 | Unknown status | Phase 3 | Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | January 2011 | April 2018 |
| NCT01237704 | Unknown status | N/A | Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy | January 2011 | December 2014 |
| NCT05146050 | Unknown status | Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma | December 8, 2021 | December 1, 2022 | |
| NCT03411954 | Unknown status | Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients | January 1, 2018 | March 2022 | |
| NCT03557112 | Unknown status | Phase 2 | By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | June 1, 2018 | December 1, 2021 |
| NCT03403829 | Unknown status | Phase 3 | Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage | January 1, 2018 | December 31, 2020 |
| NCT03568032 | Unknown status | Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal Carcinoma | July 1, 2018 | June 30, 2019 | |
| NCT03578575 | Unknown status | Phase 2 | To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma | July 26, 2018 | July 31, 2020 |
| NCT03588403 | Unknown status | TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients | July 1, 2018 | July 31, 2022 | |
| NCT03346109 | Unknown status | N/A | To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma | November 16, 2017 | December 30, 2022 |
| NCT03601975 | Unknown status | Phase 3 | Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma | August 27, 2018 | July 30, 2021 |
| NCT03612219 | Unknown status | Phase 2 | Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma | July 1, 2018 | July 28, 2021 |
| NCT03647527 | Unknown status | Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy | September 1, 2016 | January 31, 2019 | |
| NCT03648697 | Unknown status | Phase 2 | EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC | October 10, 2018 | October 10, 2021 |
| NCT05162872 | Unknown status | Phase 2 | Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma | August 5, 2021 | October 30, 2023 |
| NCT03344068 | Unknown status | Phase 2/Phase 3 | Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma | January 1, 2018 | March 31, 2021 |
| NCT03668730 | Unknown status | Phase 2 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | October 19, 2018 | December 30, 2023 |
| NCT03290001 | Unknown status | The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients | August 20, 2017 | September 20, 2022 | |
| NCT03701451 | Unknown status | Phase 1/Phase 2 | Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma | February 28, 2018 | December 1, 2020 |
| NCT03707509 | Unknown status | Phase 3 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | November 13, 2018 | December 31, 2022 |
| NCT03213587 | Unknown status | Phase 2 | Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | July 1, 2017 | July 2020 |
| NCT03720340 | Unknown status | Phase 3 | Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis | October 1, 2018 | August 30, 2022 |
| NCT03202173 | Unknown status | N/A | The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy | January 1, 2017 | June 30, 2018 |
| NCT03130270 | Unknown status | Phase 2 | Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma | January 1, 2017 | December 8, 2019 |
| NCT03087695 | Unknown status | Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma | April 1, 2017 | January 16, 2019 | |
| NCT03830996 | Unknown status | Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma | February 2016 | December 2020 | |
| NCT00155181 | Unknown status | Molecular Mechanism of Nasopharyngeal Carcinoma | January 2005 | August 2005 | |
| NCT03068936 | Unknown status | Phase 3 | IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma | March 2017 | September 2021 |
| NCT03058432 | Unknown status | Phase 2 | Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | January 2017 | December 2019 |
| NCT03048305 | Unknown status | Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue | February 1, 2017 | January 2023 | |
| NCT03854838 | Unknown status | Phase 2 | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | May 1, 2019 | February 1, 2023 |
| NCT03047525 | Unknown status | Phase 1/Phase 2 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | February 20, 2017 | December 1, 2020 |
| NCT03045484 | Unknown status | N/A | Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy | May 2016 | June 2018 |
| NCT03025854 | Unknown status | Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma | January 2017 | January 2023 | |
| NCT03020329 | Unknown status | Phase 2 | Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | November 14, 2016 | December 30, 2022 |
| NCT03904225 | Unknown status | Phase 2 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | December 14, 2018 | December 2022 |
| NCT03006588 | Unknown status | Phase 2/Phase 3 | EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients | January 2014 | December 2018 |
| NCT03915132 | Unknown status | Phase 2 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | May 1, 2019 | May 1, 2022 |
| NCT03923842 | Unknown status | Phase 2 | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours | June 30, 2019 | October 30, 2022 |
| NCT02958111 | Unknown status | Phase 3 | Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | January 2017 | December 2023 |
| NCT03925896 | Unknown status | Phase 1 | Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients | August 7, 2019 | August 1, 2022 |
| NCT03932266 | Unknown status | Phase 2 | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma | June 2019 | September 2023 |
| NCT02016417 | Unknown status | Phase 2 | Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma | May 2014 | December 2020 |
| NCT02944708 | Unknown status | Phase 3 | Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma | October 2015 | October 2018 |
| NCT02915432 | Unknown status | Phase 1/Phase 2 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | December 2016 | April 30, 2022 |
| NCT02907710 | Unknown status | Phase 3 | Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma | October 2016 | November 2019 |
| NCT02878889 | Unknown status | Phase 2 | A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. | August 2016 | |
| NCT04004871 | Unknown status | Phase 2 | Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma | July 5, 2019 | June 30, 2022 |
| NCT04014738 | Unknown status | The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma | July 20, 2019 | December 2020 | |
| NCT04015661 | Unknown status | Phase 2 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | July 9, 2019 | June 1, 2022 |
| NCT01884987 | Unknown status | Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study | January 2012 | December 2014 | |
| NCT04061278 | Unknown status | Phase 3 | A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients | August 1, 2019 | December 31, 2022 |
| NCT02871518 | Unknown status | Phase 2 | Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma | August 2016 | July 2021 |
| NCT04073784 | Unknown status | Phase 1 | Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. | June 8, 2019 | April 1, 2024 |
| NCT01479504 | Unknown status | Phase 3 | A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | November 2011 | December 2017 |
| NCT02854410 | Unknown status | N/A | Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients | August 2016 | December 2018 |
| NCT04107142 | Unknown status | Phase 1 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | December 1, 2019 | March 1, 2021 |
| NCT01872962 | Unknown status | Phase 3 | Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | November 2013 | November 2020 |
| NCT04158518 | Unknown status | N/A | De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma | November 1, 2019 | December 31, 2022 |
| NCT02795195 | Unknown status | Phase 1/Phase 2 | Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma | January 2016 | December 2020 |
| NCT04220528 | Unknown status | Phase 2 | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC | December 1, 2019 | December 1, 2023 |
| NCT02786641 | Unknown status | Phase 3 | Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma | August 2016 | August 2021 |
| NCT01182909 | Unknown status | Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC) | August 2010 | December 2014 | |
| NCT02761291 | Unknown status | Phase 1 | Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma | May 2016 | |
| NCT04282070 | Unknown status | Phase 1 | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | March 27, 2020 | December 15, 2022 |
| NCT04292990 | Unknown status | Phase 4 | Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients | December 2020 | December 2021 |
| NCT04303975 | Unknown status | The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma | June 2021 | December 2021 | |
| NCT04319471 | Unknown status | Phase 2 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | June 1, 2020 | June 1, 2023 |
| NCT02636231 | Unknown status | Phase 2 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | November 2015 | December 2021 |
| NCT02633202 | Unknown status | Phase 3 | Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era | November 2015 | December 2021 |
| NCT02633176 | Unknown status | Phase 3 | Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma | January 2015 | |
| NCT02621970 | Unknown status | Phase 3 | Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma | January 2016 | January 2024 |
| NCT02610556 | Unknown status | Phase 2 | Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma | January 2016 | January 2022 |
| NCT04394091 | Unknown status | Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients | May 20, 2020 | December 20, 2020 | |
| NCT02590133 | Unknown status | Phase 2 | A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC | July 2015 | December 2020 |
| NCT00816816 | Unknown status | Phase 2 | Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma | February 2007 | June 2010 |
| NCT00705627 | Unknown status | Phase 3 | A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | June 2008 | June 2017 |
| NCT00817583 | Unknown status | Phase 2 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC) | January 2009 | July 2011 |
| NCT02293356 | Unknown status | Phase 4 | Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma | August 2015 | December 2017 |
| NCT04895345 | Unknown status | Phase 2 | A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma | June 15, 2021 | June 30, 2023 |
| NCT00677118 | Unknown status | Phase 3 | Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | June 2006 | March 2015 |
| NCT02187315 | Unknown status | Phase 2 | Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study | May 2014 | December 2019 |
| NCT02111460 | Unknown status | Phase 3 | Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma | October 2013 | December 2022 |
| NCT02096380 | Unknown status | The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | May 2014 | December 2018 | |
| NCT01417390 | Unknown status | Phase 2 | Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | November 2011 | December 2015 |
| NCT04955886 | Unknown status | Phase 2 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | August 2021 | August 2023 |
| NCT01612286 | Unknown status | Phase 2 | Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma | May 2012 | May 2014 |
| NCT01536223 | Unknown status | Phase 3 | Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma | April 2012 | February 2015 |
| NCT04992988 | Unknown status | Phase 2 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | June 28, 2020 | June 2022 |
| NCT02089204 | Unknown status | Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma | June 2010 | December 2015 | |
| NCT04764149 | Unknown status | Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma | November 1, 2019 | June 30, 2022 | |
| NCT02328261 | Unknown status | Phase 2 | A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma | November 2014 | April 2017 |
| NCT02301208 | Unknown status | Phase 3 | Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma | December 2014 | |
| NCT04810936 | Unknown status | N/A | Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy | July 26, 2019 | December 31, 2022 |
| NCT01614938 | Unknown status | Phase 2 | Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer | August 2010 | August 2014 |
| NCT02537925 | Unknown status | Phase 3 | The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma | January 2014 | December 2016 |
| NCT02505672 | Unknown status | Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma | August 2016 | ||
| NCT04419324 | Unknown status | N/A | To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer | June 2020 | May 2021 |
| NCT04421469 | Unknown status | Phase 2 | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC | June 15, 2020 | June 15, 2023 |
| NCT01462903 | Unknown status | Phase 1 | A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors | September 2011 | December 2014 |
| NCT05292027 | Unknown status | N/A | Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | March 20, 2022 | June 20, 2022 |
| NCT02500940 | Unknown status | Phase 3 | Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma | May 2015 | May 2021 |
| NCT01854203 | Unknown status | Phase 2/Phase 3 | Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC | July 2013 | December 2016 |
| NCT00364962 | Unknown status | Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients | April 2006 | June 2006 | |
| NCT05330169 | Unknown status | Hearing Toxicity of Nasopharyngeal Carcinoma After Chemoradiotherapy | July 1, 2022 | December 31, 2023 | |
| NCT01821495 | Unknown status | Phase 2 | Study of DC-CIK to Treat NPC | May 2013 | May 2018 |
| NCT04472403 | Unknown status | Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma | November 26, 2019 | December 2020 | |
| NCT02481089 | Unknown status | Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma | June 2015 | ||
| NCT01817023 | Unknown status | Phase 3 | The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT | April 2013 | March 30, 2021 |
| NCT00817258 | Unknown status | Phase 2 | Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma | January 2007 | December 2009 |
| NCT04528394 | Unknown status | Phase 2 | Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma | April 29, 2019 | June 30, 2022 |
| NCT02476669 | Unknown status | Serial Plasma EBV DNA for Nasopharyngeal Carcinoma | June 2010 | December 2021 | |
| NCT00816855 | Unknown status | Phase 2 | Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma | February 2007 | June 2010 |
| NCT04547088 | Unknown status | Phase 2 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | September 2020 | October 2023 |
| NCT04548271 | Unknown status | Phase 2 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | September 2020 | October 2023 |
| NCT04553510 | Unknown status | Phase 2 | Treatment of Bevacizumab Followed by Steroid in RN | January 1, 2016 | June 30, 2021 |
| NCT02434614 | Unknown status | Phase 3 | Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | March 2015 | December 2021 |
| NCT01086488 | Unknown status | Phase 2 | Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma | January 2009 | October 2011 |
| NCT02421640 | Unknown status | Phase 2 | Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC | March 2015 | March 2020 |
| NCT02401763 | Unknown status | Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis | April 2015 | ||
| NCT02363400 | Unknown status | Phase 3 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | November 2014 | December 2022 |
| NCT04745741 | Unknown status | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC | May 1, 2021 | June 1, 2021 | |
| NCT00367718 | Withdrawn | Phase 2 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | ||
| NCT03390738 | Withdrawn | Phase 2 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | June 2018 | June 2019 |
| NCT02289807 | Withdrawn | N/A | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy | March 2015 | August 2022 |
| NCT00181220 | Withdrawn | Phase 1 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma | April 2004 | September 2006 |
| NCT00515957 | Withdrawn | Phase 1 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | August 2007 | August 2010 |
- OrphaNumber from OrphaNet (Orphanet)
- 150
- MedGen concept unique identifier (MedGen Concept name)
- CN199582
- MedGen unique identifier (MedGen Concept name)
- 1432650